Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.

British journal of clinical pharmacology - 1 May 2006

Feng Yan, Pollock Bruce G, Ferrell Robert E, Kimak Mark A, Reynolds Charles F, Bies Robert R

Abstract excerpt

AIM: To develop a population pharmacokinetic (PK) model using sparse sampling of long-term treatment with paroxetine in elderly depressed subjects, incorporating CYP2D6 genotype as well as other covariates. METHODS: Elderly subjects (age>or=70 years) with nonpsychotic, nonbipolar major depressive disorder from the inpatient and outpatient clinic were treated with paroxetine in a 5-year clinical trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6 Inhibitors
Share to Depressive Disorder

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Nonlinear Dynamics

Share to Paroxetine

Share to Racial Groups

Share to Selective Serotonin Reuptake Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 16669849
DOI: 10.1111/j.1365-2125.2006.02629.x
PMCID: PMC1885048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.PMID 16669849Read ↗

Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.Semantic proximity Read ↗

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.Semantic proximity Read ↗

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.Semantic proximity Read ↗

Paroxetine pharmacokinetics in depressed children and adolescents.Semantic proximity Read ↗

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.Semantic proximity Read ↗

Population pharmacokinetic analysis of mirtazapine.Semantic proximity Read ↗

Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.Semantic proximity Read ↗

Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.Semantic proximity Read ↗

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.Semantic proximity Read ↗

Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.Semantic proximity Read ↗

Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.Semantic proximity Read ↗

S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.